{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m prasugrel
to a specific field?
Status:
Investigational
Source:
NCT03858634: Phase 2 Interventional Completed Chronic Idiopathic Urticaria
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00001296: Phase 3 Interventional Completed Melanoma
(1992)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04655586: Phase 2/Phase 3 Interventional Completed Covid19
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04612530: Phase 1 Interventional Unknown status Pancreatic Cancer
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sampeginterferon beta-1a [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04692181: Phase 1/Phase 2 Interventional Active, not recruiting Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04295538: Phase 2 Interventional Active, not recruiting Spinal Cord Injury (SCI)
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00996255: Phase 1 Interventional Terminated Advanced/Metastatic Solid Tumors
(2006)
Source URL:
Class:
PROTEIN
Targets:
Conditions:
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 uM. In colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 uM indicating that it has efficient and prolonged antiproliferative activity. PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation. PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo.
